On November 5, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, reported that new preclinical data from its kt-5000AI ATR inhibitor program will be presented in a poster at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15, 2026, in Philadelphia, Pennsylvania.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster describes brain-penetrant inhibitors of ataxia telangiectasia and Rad3-related protein kinase (ATR) developed with Variational AI Inc. ("Variational AI") using its Enki generative AI platform. The compounds were designed for tumours that have lost the tumour-suppressor gene PTEN, a vulnerability found in gliomas and in cancers that commonly spread to the brain.
The program initially explored dual ATR and mTOR inhibition, as reflected in the abstract title. Lead optimization has since converged on ATR-selective compounds, and kt-5000AI is now focused on brain-penetrant ATR inhibition.
Presentation Details
Title: Brain-penetrant dual ATR-mTOR inhibitors for PTEN-deficient cancers
Abstract Code: DNAR-04
Format: Poster Presentation
Date and Time: Friday, November 13, 2026, 7:30 to 9:30 p.m. EST
Location: Exhibit Hall D & E, Pennsylvania Convention Center, Philadelphia, Pennsylvania
As announced on October 22, 2026, the kt-5000AI program has advanced from target specification to an advanced lead-optimization stage in approximately two years using the Enki platform. Optimized compounds have demonstrated potent and selective ATR inhibition, improved metabolic stability, and permeability and efflux characteristics associated with brain penetration. Studies to characterize CNS exposure in the optimized series are ongoing.
"The Society for Neuro-Oncology provides an important opportunity to present our research to leading clinicians and scientists focused on advancing treatments for brain cancers," said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. "PTEN-deficient tumours may be particularly vulnerable to ATR inhibition, presenting a compelling opportunity for targeted therapeutic development. Our kt-5000AI program was designed specifically to address this limitation, combining potent and selective ATR inhibition with the potential to reach tumours within the central nervous system."
Webinar Today
Rakovina will host a joint webinar with Variational AI today, November 5, 2026, at 9:30 a.m. Vancouver time (11:30 a.m. Toronto time), to discuss the kt-5000AI program and its progress to date, including the results described in the recently published case study. The webinar will feature Kim Oishi, Chief Executive Officer, and Dr. Mads Daugaard, President and Chief Scientific Officer, of Rakovina Therapeutics, and Handol Kim, Co-Founder and Chief Executive Officer of Variational AI. Registration is available at View Source
About the Society for Neuro-Oncology
The Society for Neuro-Oncology (SNO) is a multidisciplinary organization dedicated to advancing brain tumour research, education and collaboration to drive discovery and improve patient care. The 31st SNO Annual Meeting & Education Day, themed "Crossing the Translational Divide: From Neurons to Novel Therapies," focuses on the research, diagnosis and treatment of central nervous system malignancies. More information is available at www.soc-neuro-onc.org.
(Press release, Rakovina Therapeutics, NOV 5, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-to-present-brain-penetrant-atr-inhibitor-data [SID1234674323])